Abstract:SESSION TITLE: Lung Cancer: Diagnosis and Prognosis SESSION TYPE: Original Investigation Slide PRESENTED ON: Saturday, April 16, 2016 at 09:45 AM - 11:15 AM PURPOSE: The purpose of this retrospective study was to evaluate the impact of visceral pleural invasion (VPI) and tumer size ranged 3 to 7cm on overall survival (OS) in surgically resected early stage non-small cell lung cancer (NSCLC) patients with pathologic N0M0. METHODS: We retrospectively reviewed the clinicopathological characteristics and outcomes of 207 patients with tumor size lesser than 7cm, with surgically resected pathologic stage pN0M0 NSCLC between January 2008 and December 2013 at the West China hospital, Sichuan University. We used the Kaplan-Meier method to assess the association of VPI and tumor size with overall survival (OS). Cox proportional hazards regression model was used for multivariate analyses. RESULTS: 101 patients (48.8%) had presence VPI, and 106 patients (52.2%) without. Median follow-up was 40.5 months. The 5-year overall survival rate was 80.0% and 63.6% for those with tumor size smaller than 3cm and tumor size ranged 3-5cm, respectively. Kaplan-Meier survival analysis stratified by tumor size showed worse overall survival in patients with VPI (P=0001). And survival rates decreased when the size of the tumor increased (p=0.001). There was a significant effect for the VPI and tumor size (rang 3 to 5cm) interactions for OS (p=0.006), the effects of VPI for other tumor size groups were not significant. Overall survival between tumor size ranged 3-5cm with VPI and tumor size ranged 5-7cm without VPI was not significant (p=0.192). In multivariate analysis, VPI, larger tumor size, older age were significantly associated with decreased OS. CONCLUSIONS: Our results suggest that the presence of VPI did not influence the overall survival in operated non-small lung cancer patients with tumor size lesser than 3cm, however, VPI decreased overall survival in patients with tumor size ranged 3-5cm. In our study, we suggested that tumors lesser than 3cm with VPI should be treated as T1a not T2, and that tumor size ranged 3 to 5cm could be upstaged to the next T stage in the further TNM staging system. Further larger scale studies with more patients, longer-time follow-up and the depth of VPI should be re-evaluated. CLINICAL IMPLICATIONS: It thus remains controversial whether the presence of VPI affects overall survival and influenced the upstage according to the tumor size in patients with resected NSCLC. Our study suggested that tumors lesser than 3cm with VPI should be treated as T1a not T2, and that tumor size ranged 3 to 5cm could be upstaged to the next T stage in the further TNM staging system DISCLOSURE: The following authors have nothing to disclose: Ping Zhou, Yuting Jing, Weimin Li No Product/Research Disclosure Information

The prognosis and treatment consideration for non-small cell lung carcinoma patients with tumor size of >2.0–3.0 cm and visceral pleural invasion: a SEER-based study

Diagnosis, treatment, and prognosis of stage IB non-small cell lung cancer with visceral pleural invasion

Prognostic Value of Visceral Pleural Invasion in Non-Small Cell Lung Cancer: A Propensity Score Matching Study Based on the SEER Registry.

Effect of visceral pleural invasion on the prognosis of patients with lymph node negative non-small cell lung cancer

The modification of T description according to visceral pleural invasion and tumor size from 3.1 cm to 4.0 cm in non-small cell lung cancer: A retrospective analysis based on the SEER database

Treatment Modality for Stage IB Peripheral Non-Small Cell Lung Cancer With Visceral Pleural Invasion and ≤3 cm in Size

Sublobectomy Versus Lobectomy for Long-Term Survival Outcomes of Early-Stage Non-Small Cell Lung Cancer with a Tumor Size ≤2 Cm Accompanied by Visceral Pleural Invasion: a SEER Population-Based Study

CT Predictors of Visceral Pleural Invasion in Patients with Non-Small Cell Lung Cancers 30 mm or Smaller

Visceral pleural invasion predict a poor survival among lung adenocarcinoma patients with tumor size ≤ 3cm.

Prognosis evaluation and efficacy analysis of different treatment options for patients with visceral pleural invasion in stage IIA-IIB lung cancer

The Location of Visceral Pleural Invasion in Stage IB Patients with Non-Small Cell Lung Cancer: Comparison and Prognosis.

Visceral Pleural Invasion Decreased Overall Survival in Resected Non-Small Cell Lung Cancer Patients with Tumor Size Ranged 3 to 5 Cm Rather Than 3 Cm or Less

Real-world Surgical Treatment Patterns and Clinical Outcomes in Patients with Stages IA–IIIA Non-Small Cell Lung Cancer: a Retrospective Multicentric Observational Study Involving 11,958 Patients

The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung

Prognostic factors and treatment comparison in small cell neuroendocrine carcinoma of the uterine cervix based on population analyses

Choice of the Surgical Approach for Patients with Stage I Lung Squamous Cell Carcinoma ≤3 Cm

Impact of treatment modality on long-term survival of stage IA small-cell lung cancer patients: a cohort study of the U.S. SEER database

[Study on the Prognosis of the T1a Non-Small Cell Lung Cancer].

Influence of pleural invasion on survival in pathologic T3–4N0M0 non-small cell lung cancer: a propensity score matching study based on the Surveillance, Epidemiology, and End Results database

Choice of Treatment for Patients with Non–small-cell Lung Cancer >5 Cm Between Surgery Alone and Surgery Plus Adjuvant Radiotherapy

Prognostic Factors and Treatment Comparison in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix in the Surveillance, Epidemiology, and End Results Database.